Skip to content
Medical Health Aged Care

Bondi2Berry Ride to Remember celebrates 10 years raising funds for dementia research

Dementia Australia 3 mins read

Dementia Australia is proud to support the Bondi2Berry Ride to Remember, which marks its 10-year anniversary this Saturday, 15 November 2025.

More than 300 riders and event crew will take part in the 155km ride from Bondi Beach through the Royal National Park to Wollongong, Kiama and finishing in Berry.

Since its inception in 2016, Bondi2Berry has raised more than $1.9 million, funding 11 dementia research projects. This year, organisers aim to raise $250,000, which will directly fund two new research projects through the Dementia Research Community charity.

Dementia Australia CEO Professor Tanya Buchanan said the event is an inspiring example of community action promoting brain health.

“I extend my appreciation to the Bondi2Berry organisers, riders and sponsors for their commitment to raising awareness and funds for dementia research,” Professor Buchanan said.

“Dementia is now the leading cause of death of Australians[1], and without a significant intervention, the number of Australians living with dementia is expected to increase to more than 1 million by 2065[2].

“Bondi2Berry supports vital dementia research while promoting healthy habits like exercise and social connection - that both support brain health and can reduce dementia risk.”

Bondi2Berry co-founder Nick Young said this year's milestone event marks a decade of dedication to raising awareness and funds for dementia research.

“What started as a small group of riders has grown into a powerful community united by one goal: to raise awareness and vital funds for dementia research,” Young said. 

“This milestone is a tribute to every rider, volunteer, sponsor, supporter and donor who has helped drive progress towards a future without dementia.

“As a voluntary committee, all funds raised from our charity go directly to research and we hope to support two research projects from this year’s ride.”

The ride will include a public event at Hindmarsh Park, Kiama at 11am, hosted by Kiama Municipal Council, celebrating Kiama’s status as a dementia-friendly community. Bondi2Berry ambassadors participating in this year’s event include Craig Alexander, Ironman World Champion; Emily Watts and Josie Talbot, professional cyclists; and riders like Nicole Stanners and Jay Gaffey, all of whom have a personal connection to dementia.

To find out more or donate to riders participating in this year’s event, visit:  https://drc.supporterhub.net.au/fundraising/bondi2berry-2025/bondi2berry

-Ends-

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Andrea Hogan, Media Relations & Communications Manager, 0406 904 118, [email protected]

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.



[1]  Australian Institute of Health and Welfare (2025) Dementia in Australia, AIHW, Australian Government, accessed 12 September 2025. 

[2]  Australian Institute of Health and Welfare (2025) Dementia in Australia, AIHW, Australian Government, accessed 12 September 2025. 

 

Media

More from this category

  • Medical Health Aged Care
  • 03/03/2026
  • 02:26
Tilray Brands, Inc.

Tilray Brands Acquires BrewDog, a Leading Global Craft Brand, Creating a ~$500 Million Global Craft Beer and Beverage Platform

Accretive Acquisition of Select Assets Includes Global Brand, UK Brewing Operations and 11 Strategic Brewpubs Expected to Generate ~$200 Million in Annual Net Revenue and ~$6 - $8 Million of Adjusted EBITDA in Fiscal 2027Tilray’s Global Consolidated Net Revenue Expected to Reach ~$1.2 Billion on an Annualized Basis1Conference Call Scheduled for 12:30pm ETNEW YORK and LONDON, March 02, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today completed the acquisition of certain highly…

  • Medical Health Aged Care
  • 02/03/2026
  • 23:11
SBC Medical Group Holdings Incorporated

SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure

IRVINE, Calif.–BUSINESS WIRE– SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services…

  • Contains:
  • Medical Health Aged Care
  • 02/03/2026
  • 18:11
Takeda Pharmaceutical Company Limited

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Rusfertide Demonstrated Significant Improvements in Hematocrit Control, Phlebotomy Reduction and Patient Reported Outcomes for Patients with Polycythemia Vera in a Pivotal StudySubmission Primarily Based on Phase 3 VERIFY Study, in Which Rusfertide Plus Standard of Care More Than Doubled Clinical Response Rates, as Well as Four-Year Efficacy and Safety Data from Phase 2 REVIVE/THRIVE StudiesPrescription Drug User Fee Act (PDUFA) Target Action Date is in the Third Quarter of this Calendar Year OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--BUSINESS WIRE-- Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.